Form 4: SOPHiA GENETICS Officer Sells Shares

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported a sale of 608 ordinary shares for $4.6059 each, executed under a Rule 10b5-1(c) trading plan.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 608 ordinary shares on May 19, 2026.
• The sale was conducted at a weighted average price of $4.6059 per share, with individual transactions ranging from $4.54 to $4.66.
• These shares were sold to cover tax withholding obligations related to the vesting of restricted stock units on May 18, 2026.
• The transactions were executed as part of a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• Following these transactions, Philippe Menu beneficially owns 255,780 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sale can be perceived negatively, the clear explanation of it being for tax withholding under a pre-arranged plan mitigates significant concern.

Positives

• The sale was conducted under a Rule 10b5-1(c) trading plan, which is designed to comply with insider trading regulations and demonstrates adherence to pre-planned financial management.
• The sale was to satisfy tax withholding obligations, a common and expected event for executives upon vesting of equity awards.
• Philippe Menu retains a significant beneficial ownership of 255,780 ordinary shares, indicating continued alignment with the company's long-term success.

Negatives

• A sale of company stock by a key executive, even if pre-planned, can sometimes be perceived negatively by the market.
• The weighted average sale price of $4.6059 per share may be lower than the current market price, depending on the prevailing stock valuation at the time of the filing.

Risks

• The filing does not explicitly mention any new or emerging risks.
• Potential market perception of insider selling could negatively impact share price, although this is mitigated by the Rule 10b5-1(c) plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on a past transaction.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the range set forth in this footnote upon written request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1(c) plan by SOPHiA GENETICS SA's Chief Medical Officer is a common practice for executives to manage their equity holdings in a compliant manner, especially for covering tax liabilities.

Stakeholder Impact

• Shareholders: May observe the sale, but the Rule 10b5-1(c) plan context suggests it's a planned event rather than a signal of negative sentiment.
• Employees: The sale is related to equity vesting and tax obligations, which is a standard executive compensation practice.
• Management: Demonstrates adherence to regulatory requirements for reporting insider transactions.

Next Steps

• No specific next steps are outlined in this filing.
• The company's ongoing operations and future financial performance will be detailed in subsequent SEC filings.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Share Sale, Rule 10b5-1, Restricted Stock Units, Tax Withholding, Philippe Menu, Chief Medical Officer, Beneficial Ownership